Atlas Trials

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Clinical trial NCT00101166 · COMPLETED

Trial details

NCT number
NCT00101166
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma (Skin)
Start date
2004-10-01
Primary completion
2010-03-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.